Parkinson’s disease (PD) is a progressive neurological disorder that affects movement. Diagnosing Parkinson’s can sometimes be complex, as its early symptoms can be subtle and overlap with other conditions. To aid in the diagnostic process, medical science has developed sophisticated tools, and among them is the Dopamine Transporter Scan, commonly known as DaTscan. Approved by the Food and Drug Administration (FDA) in 2011, DaTscan is an imaging test that helps clinicians visualize the dopamine system in the brain, playing a crucial role in confirming or excluding Parkinson’s disease.
What is a Dopamine Transporter Scan (DaTscan) and How Does It Work?
The Dopamine Transporter Scan (DaTscan) is a specialized nuclear medicine imaging test designed to assess the function of dopamine neurons in the brain. Dopamine is a neurotransmitter vital for movement control, and its deficiency is a hallmark of Parkinson’s disease. DaTscan utilizes a radioactive tracer called Ioflupane (123I), which is also known as DaTscan. This tracer is injected intravenously and travels through the bloodstream, eventually reaching the brain.
Once in the brain, the DaTscan tracer binds to dopamine transporters (DaTs). These transporters are proteins located on the surface of dopamine neurons, responsible for regulating dopamine levels. In individuals with Parkinson’s disease, there is a reduction in dopamine neurons and, consequently, in dopamine transporters in specific brain regions, particularly the striatum.
Several hours after the injection, a specialized gamma camera detects the distribution of the radioactive tracer in the brain. This imaging equipment captures signals emitted by the tracer, creating images that reflect the density of dopamine transporters. These images are then interpreted by nuclear medicine physicians or radiologists to assess the integrity of the dopamine system.
A typical DaTscan report compares the patient’s scan to a normal scan. In a healthy individual, the DaTscan image shows a characteristic comma-shaped or crescent-shaped uptake in the striatum, indicating a normal density of dopamine transporters. Conversely, in individuals with Parkinson’s disease, the DaTscan image often reveals a reduced, less intense signal in the striatum. This reduction signifies a loss of dopamine transporters, supporting the diagnosis of Parkinsonian syndromes.
Normal vs Abnormal DaTscan: Brain scans illustrating a healthy dopamine system (left) and a dopamine-depleted system indicative of Parkinson's disease (right).
It’s important to emphasize that standard Magnetic Resonance Imaging (MRI) scans, while valuable for ruling out other neurological conditions, typically appear normal in Parkinson’s disease. Therefore, MRI is not a primary tool for confirming a Parkinson’s diagnosis. However, in cases of atypical parkinsonism or vascular parkinsonism, MRI might show abnormalities, making DaTscan even more relevant in differential diagnosis.
DaTscan Accuracy in Parkinson’s Diagnosis
When motor symptoms of Parkinson’s become apparent, the accuracy of diagnosing Parkinson’s using DaTscan is comparable to diagnosis based on a thorough clinical examination by a neurologist. In many instances, experienced neurologists can accurately diagnose Parkinson’s through clinical assessment alone, as Parkinson’s presents with distinct motor and non-motor features that can be identified during a neurological exam. These features include tremor, bradykinesia (slowness of movement), rigidity, and postural instability.
Despite the availability of DaTscan to aid in diagnosing Parkinson’s, its added value in routine clinical practice is often limited when a clear clinical diagnosis can be made. Research studies have even indicated that the diagnostic accuracy in early Parkinson’s disease is similar whether diagnosis is based solely on clinical examination or incorporates DaTscan results. This underscores the expertise of neurologists in recognizing Parkinson’s through clinical signs and symptoms.
Limitations and Potential Pitfalls of DaTscan
While DaTscan is a valuable tool, it’s crucial to understand its limitations. An abnormal DaTscan result indicates a loss of dopamine nerve terminals in the striatum, but it is not specific to Parkinson’s disease. Several neurological conditions, known as Parkinson-plus syndromes, also result in dopamine neuron degeneration and will therefore show abnormal DaTscans. These conditions include Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Multiple System Atrophy (MSA). DaTscan cannot differentiate between Parkinson’s disease and these Parkinson-plus syndromes.
Like all medical tests, DaTscan has a possibility of false positive and false negative results. A false positive result occurs when the DaTscan is abnormal in someone who does not have Parkinson’s or a related syndrome, while a false negative result is when the DaTscan is normal in someone who actually has the condition. These false results are relatively uncommon but highlight that DaTscan results must always be interpreted in conjunction with the overall clinical picture, including patient history, neurological examination findings, and other relevant investigations.
When is DaTscan Particularly Helpful?
DaTscan becomes most valuable in situations where the neurological examination findings are not clear-cut, and there is diagnostic uncertainty. Although DaTscan cannot distinguish Parkinson’s disease from PSP, CBD, or MSA, studies suggest it can be helpful in differentiating Parkinson’s disease from other conditions that mimic Parkinsonism, such as drug-induced parkinsonism and vascular parkinsonism. Drug-induced parkinsonism can arise as a side effect of certain medications, while vascular parkinsonism results from small strokes in the brain.
The FDA’s approved indication for DaTscan is to help differentiate between Parkinsonian syndromes and essential tremor (ET). Essential tremor is a common movement disorder characterized by tremor, but unlike Parkinson’s, it is not associated with dopamine deficiency. In most cases, neurologists can readily distinguish between the tremor of ET and the tremor of Parkinson’s disease clinically. Parkinson’s tremor is typically a resting tremor, occurring when the limb is at rest, and is often accompanied by bradykinesia and rigidity. Essential tremor, on the other hand, is usually an action tremor, most prominent during voluntary movement, and is not associated with slowness or stiffness.
However, some individuals may present with tremor characteristics that are not typical, making the differentiation between ET and Parkinson’s disease challenging. In these ambiguous cases, DaTscan can provide objective evidence by assessing the dopamine system. A normal DaTscan would suggest essential tremor, while an abnormal DaTscan would raise suspicion for Parkinsonian syndromes.
Limitations Regarding Disease Progression Monitoring
Currently available DaTscan technology is primarily qualitative rather than quantitative in clinical practice. This means that DaTscan is designed to determine whether there is dopamine transporter dysfunction, but it does not precisely measure the degree of dopamine system impairment. Consequently, DaTscan is not used to track the progression of Parkinson’s disease over time or to monitor an individual patient’s disease course. It provides a snapshot of dopamine transporter status at a specific point in time but does not offer detailed information about the rate of dopamine neuron loss or treatment response.
DaTscan and Pre-Motor Parkinson’s Disease Detection
Intriguingly, DaTscan can detect abnormalities in the dopamine system even before the emergence of noticeable motor symptoms of Parkinson’s disease. Research studies have shown that individuals in the pre-motor phase of Parkinson’s, who may have subtle non-motor symptoms like loss of smell or REM sleep behavior disorder, can already exhibit abnormal DaTscan results.
However, DaTscan is not currently used as a routine screening tool to detect Parkinson’s disease before motor symptoms develop in clinical practice. The Parkinson’s disease research community is actively exploring new diagnostic approaches, focusing on identifying biomarkers – measurable indicators of disease – that can facilitate earlier diagnosis.
One promising concept is a biological staging system for Parkinson’s disease, proposing a condition termed Neuronal Synuclein Disease (NSD). NSD is characterized by both dopaminergic neuron dysfunction, detectable by DaTscan, and abnormal alpha-synuclein aggregation, detectable through lumbar puncture. Both of these biological abnormalities can be present years before motor symptoms of Parkinson’s become clinically evident.
This research direction holds exciting potential for the future of Parkinson’s disease management. Early diagnosis, even before motor symptoms manifest, could enable the inclusion of individuals with very early-stage disease in clinical trials evaluating potential disease-modifying therapies. Furthermore, if medications that can slow down or halt Parkinson’s progression are developed, they could be administered to individuals in the pre-motor phase, potentially preventing or significantly delaying the onset of full-blown Parkinson’s disease.
What to Expect During a DaTscan Procedure
The entire DaTscan procedure typically takes between 4 to 8 hours. The timeline involves several steps:
- Thyroid Protection: Approximately 1 hour before the DaTscan injection, the patient takes medication, usually in pill form, to protect the thyroid gland from absorbing radioactive iodine-123. This medication saturates the thyroid with non-radioactive iodine, preventing the uptake of the radioactive tracer by the thyroid.
- DaTscan Injection: The radioactive tracer, Ioflupane (123I) or DaTscan, is injected intravenously, usually into a vein in the arm. The injection itself is quick and generally well-tolerated.
- Waiting Period: There is a waiting period of 3 to 6 hours after the injection. During this time, the DaTscan tracer circulates in the bloodstream and crosses the blood-brain barrier to reach the brain. It then binds to dopamine transporters in the striatum. Patients can usually go about their normal activities during this waiting period but are typically asked to remain within the vicinity of the imaging center.
- Brain Scan: The actual brain scan takes about 30 minutes. The patient lies still on a scanner bed while the gamma camera, a specialized imaging device, rotates around the head to acquire images of the tracer distribution in the brain. The scan is non-invasive and painless.
Why a DaTscan Might Not Be Ordered
Many individuals diagnosed with Parkinson’s disease understandably have questions about the diagnostic process. Some patients express concerns or even skepticism when diagnosed based primarily on a neurological examination without a DaTscan. Common questions or comments include:
- “My doctor just had me do some simple movements and watched me walk, and then told me I have Parkinson’s! Is that really enough?”
- “I’m worried I might have something else. Are there other conditions that could be mistaken for Parkinson’s?”
- “How can they be completely sure? Shouldn’t there be a definitive test to confirm or rule out Parkinson’s?”
It’s essential to understand that Parkinson’s disease diagnosis remains primarily a clinical diagnosis. While biomarker research, including DaTscan and other potential tests, is advancing and may play a larger role in the future, clinical assessment by a neurologist is currently the cornerstone of Parkinson’s diagnosis.
Experienced neurologists are highly skilled in recognizing Parkinson’s disease based on its characteristic clinical features. Even in the early stages, when motor symptoms may be subtle, a trained neurologist can often confidently diagnose Parkinson’s through a careful neurological examination.
Certain clinical features are particularly suggestive of Parkinson’s disease. For example, rest tremor is a hallmark symptom rarely seen in other conditions. Neurologists are trained to differentiate rest tremor from other types of tremors. While not everyone with Parkinson’s has a rest tremor, and its absence can make diagnosis more challenging, a constellation of other clinical signs and symptoms, assessed during a standard in-office neurological exam, are highly characteristic of Parkinson’s. These include:
- Decreased blink rate
- Micrographia (small handwriting that decreases in size)
- Hypokinesia (reduced movement amplitude, especially in hands and feet, often asymmetrical)
- Rigidity (stiffness in limbs, often asymmetrical)
- Stooped posture
- Reduced arm swing while walking (often unilateral)
- Festination (shuffling gait with flat-footed steps)
- Turning en bloc (turning with multiple small steps rather than pivoting)
The presence of a combination of these motor features, especially when coupled with a history of certain non-motor symptoms that frequently precede motor onset in Parkinson’s disease, such as constipation, anosmia (loss of smell), and REM sleep behavior disorder, strengthens the clinical diagnosis.
While a neurological exam may appear brief to a patient, neurologists are trained to efficiently assess all these features. It’s also noteworthy that individuals may be unaware of some of these subtle signs, while a trained neurologist can readily identify them. Conversely, a neurologist can often reassure individuals concerned about Parkinson’s disease that their symptoms are not consistent with the condition.
In conclusion, for the majority of individuals with Parkinson’s disease, diagnosis can be accurately established through a clinical examination by a neurologist without requiring additional tests like DaTscan. However, as discussed, DaTscan can be a valuable adjunct in cases where the clinical picture is unclear, and biomarker research is ongoing to refine and potentially enhance Parkinson’s diagnosis in the future.
Tips & Takeaways
- DaTscan is a helpful test in the diagnostic process for Parkinson’s disease, but in most cases, a thorough clinical examination by a neurologist provides similar diagnostic information.
- Neurologists possess specialized expertise in diagnosing Parkinson’s disease through clinical assessment. While the exam might seem basic, neurologists are highly trained to confidently diagnose Parkinson’s in most situations.
- DaTscan can be particularly useful in differentiating Parkinson’s disease from certain conditions, such as essential tremor and drug-induced parkinsonism, but it does not distinguish Parkinson’s from Parkinson-plus syndromes. Discuss with your neurologist whether a DaTscan would be beneficial in your specific case.
- DaTscan is not designed to monitor the progression of Parkinson’s disease over time. It is used to aid in clarifying the diagnosis at a specific point but is not a test that is typically repeated during the course of the disease.
- In the future, DaTscan, in combination with other biomarker assessments, may play a role in diagnosing Parkinson’s disease even before the onset of classic motor symptoms, opening new avenues for early intervention and treatment strategies.
Have a Question About Parkinson’s Disease?
For expert information and resources to address your questions and concerns about Parkinson’s disease, reach out to our Scientific & Medical Affairs Department.
Ask a Doctor
